News | February 04, 2008

Long QT Syndrome Diagnostic Test Meets BCBS Criteria

February 5, 2008 - The FAMILION test for Long QT Syndrome (LQTS) has met the Blue Cross and Blue Shield Association Technology Evaluation Center’s (TEC) criteria for establishing the diagnosis of LQTS in certain individuals, representing another step toward personalized medicine.

TEC completed this assessment at its October 2007 Medical Advisory Panel meeting and posted it in online in January 2008.

In this assessment, Long QT genetic testing met TEC’s criteria for establishing the diagnosis of LQTS in two types of individuals: those who have a moderate to high pre-test probability of LQTS but do not fully satisfy the clinical criteria, as well as those who meet the clinical criteria for LQTS and have close relatives at-risk. In the latter instance, testing of the individual with LQTS is intended to inform genetic testing options for these relatives. In these populations, the FAMILION test was found to have a positive impact on net health outcomes and a positive diagnostic benefit compared to clinical diagnosis alone.

PGxHealth, a division of Clinical Data, a developer of targeted therapeutics and predictive tests using genetic biomarkers, produces TEC.

For more information: www.pgxhealth.com and www.clda.com

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Sponsored Content | Videos | Stents Bifurcation| March 06, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent.
Overlay Init